Ocrevus (ocrelizumab)

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Primary progressive MS, in adults.

In case of any adverse events or safety queries, please contact: [email protected]

If you have a scientific query related to one of Roche's products, please contact: [email protected]